News

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...
Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...
The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...
The US Food and Drug Administration (FDA) has approved Roche’s (ROG: SIX) Susvimo (ranibizumab injection) 100mg/mL for the ...
Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...
Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...
One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...
Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...
As demand grows for flexible, high-quality addiction treatment, Plugged In Recovery has launched a new outpatient program that expands its continuum of care while preserving the clinical depth and ...